The CG-100 clinical study is underway at select sites across the U.S.
If you are a rectal cancer patient between the ages of
22-65 planned to undergo a colorectal surgery
and would like to be considered for the study, click here.
Specifically designed to create a temporary intraluminal bypass
Aims to reduce the rate of diverting stoma by reducing the contact of fecal material with the anastomotic site
CG-100 is limited by U.S. law to investigational use and is not approved for sale or distribution in the US
ADDRESS: 21 Atir Yeda St, Kfa Saba, 4464316 Israel